Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Neuromodulation for the management of chronic pelvic pain syndromes: A systematic review
Gish, Brandon , Sobey, Christopher M., Singh, Chahait, Abdullah, Newaj , Walker, Jeremy, Gray, Hannah, Hagedorn, Jonathan M. , Ghosh, Priyanka , Patel, Kiran V., Hagedorn, Jonathan M , Ghosh, Priyanka , Deer, Tim , Gish, Brandon , Langford, Brendan , Deer, Timothy R.

Mayo Clinic

Pain Practice | September 20, 2023 | Volume: 24 | Issue: 2 | Pages: 321-340

10.1111/papr.13295 | PMID 37726930 Get It

AbstractBackgroundChronic pelvic pain is a burdensome condition that involves multiple medical sub‐specialties and is often difficult to treat. Sacral stimulation for functional bladder disease has been well established, but little large‐scale evidence exists regarding utilization of other neuromodulation techniques to treat chronic pelvic pain. Emerging evidence does suggest that neuromodulation is a promising treatment, and we aim to characterize the use and efficacy of such techniques for treating chronic pelvic pain syndromes.Materials and MethodsA systematic review of the literature demonstrating the treatment of chronic pelvic pain syndromes with neuromodulation. Abstracts were reviewed and selected for inclusion, including case series, prospective studies, and randomized controlled trials (RCTs). Case studies and publications in abstract only were not included. The reporting for this systematic review follows Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA). The literature search was performed using MEDLINE, Embase, Cochrane Library, PubMed, CINAHL, and Scopus.ResultsA total of 50 studies were included in this review, three of which were randomized controlled trials, and the remaining were prospective and retrospective case series. The range of pelvic pain conditions treated included interstitial cystitis, peripheral neuralgia, pudendal neuralgia, gastrointestinal pain, urogenital pain, sacroiliac joint pain, and visceral chronic pelvic pain. We reported on outcomes involving pain, functionality, psychosocial improvement, and medication reduction.ConclusionsNeuromodulation is a growing treatment for various chronic pain syndromes. Peripheral nerve stimulation was the least studied form of stimulation. Posterior tibial nerve stimulation appears to offer short‐term benefit, but long‐term results are challenging. Sacral nerve stimulation is established for use in functional bladder syndromes and appears to offer pain improvement in these patients as well. Dorsal root ganglion stimulation and spinal cord stimulation have been used for a variety of conditions with promising results. Further studies of homogeneous patient populations are necessary before strong recommendations can be made at this time, although pooled analysis may also be impactful.
Early antibody treatment, inflammation, and risk of post-COVID conditions
Heath, Sonya L. , Fukuta, Yuriko , Zhu, Xianming , Baksh, Sheriza , Abraham, Allison G., Habtehyimer, Feben , Shade, David , Ruff, Jessica E. , Ram, Malathi , Laeyendecker, Oliver , Fernández, Reinaldo E. , Patel, Eshan U. , Baker, Owen R. , Cachay, Edward R. , Gerber, Jonathan M. , Forthal, Donald N. , Hammitt, Laura L. , Huamán, Moisés A. , Patel, Bela , Gniadek, Thomas J. , Blair, Janis E. , Lane, Karen , McBee, Nichol , Gawad, Amy L., Das, Piyali, Bloch, Evan M. , Zhu, Xianming , Laeyendecker, Oliver , Patel, Eshan U , Forthal, Donald N , Sutcliffe, Catherine G , Klein, Sabra L , Pekosz, Andrew , Bloch, Evan M , Casadevall, Arturo , Tobian, Aaron A R , Sullivan, David J , Huaman, Moises A , Gebo, Kelly A , Shoham, Shmuel , Currier, Judith S. , Meisenberg, Barry R. , Levine, Adam C , Mosnaim, Giselle S , Paxton, James H , Raval, Jay S. , Anjan, Shweta , Kassaye, Seble , Hanley, Daniel F. , Casadevall, Arturo , Tobian, Aaron A.R. , Sullivan, David

Mayo Clinic

mBio | September 19, 2023 | Volume: 14 | Issue: 5 | Pages: No page available

10.1128/mbio.00618-23 | PMID 37724870 Get It

Post-COVID conditions (PCCs) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known about treatment, inflammation, and PCC. Among 882 individuals with confirmed SARS-CoV-2 infection participating in a randomized trial of COVID-19 convalescent plasma (CCP) vs control plasma with available biospecimens and symptom data, the association between early CCP treatment, cytokine levels, and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14, and day 90 using a multiplexed sandwich immunoassay (Meso Scale Discovery). Presence of any self-reported PCC symptoms was assessed at day 90. Associations between CCP treatment, cytokine levels, and PCC were examined using multivariate logistic regression models. One third of the 882 participants had day 90 PCC symptoms, with fatigue (14.5%) and anosmia (14.5%) being most common. Cytokine levels decreased from baseline to day 90. In a multivariable analysis, female sex (adjusted odds ratio [AOR] = 2.69 [1.93–3.81]), older age (AOR = 1.32 [1.17–1.50]), and elevated baseline levels of IL-6 (AOR = 1.59 [1.02–2.47]) were independently associated with development of PCC. Those who received early CCP treatment (≤5 days after symptom onset) compared to late CCP treatment had statistically significant lower odds of PCC. IMPORTANCE Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development.
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors
Abuzakhm, Sonia, Sukrithan, Vineeth , Fruth, Briant, Qin, Rui , Strosberg, Jonathan , Hobday, Timothy J. , Reidy‐Lagunes, Diane , Kindler, Hedy L. , Kim, George P., Knox, Jennifer J. , Kaubisch, Andreas , Villalona‐Calero, Miguel A. , Erlichman, Charles , Shah, Manisha H. , Strosberg, Jonathan R , Knox, Jennifer J , Sukrithan, Vineeth , Semrad, Thomas John , Chen, Helen

Mayo Clinic

Endocrine-Related Cancer | September 13, 2023 | Volume: 30 | Issue: 11 | Pages: No page available

10.1530/erc-22-0301 | PMID 37702588 Get It

We assessed the efficacy and safety of combining bevacizumab with temsirolimus in patients with advanced extra-pancreatic neuroendocrine tumors. This NCI-sponsored multicenter, open-label, phase II study (NCT01010126) enrolled patients with advanced, recurrent, or metastatic extra-pancreatic neuroendocrine tumors. All patients were treated with temsirolimus and bevacizumab until disease progression or unacceptable toxicity. Temsirolimus 25 mg was administered i.v. on days 1, 8, 15, and 22 and bevacizumab 10 mg/kg i.v. on days 1 and 15 of a 4-week cycle. Discontinuation of temsirolimus or bevacizumab did not require discontinuation of the other agent. The primary endpoints were objective response rate and 6-month progression-free survival rate. Fifty-nine patients were enrolled in this study, and 54 were evaluated for efficacy and adverse events. While median progression-free survival was 7.1 months, the median duration of treatment with temsirolimus was 3.9 months and that with bevacizumab was 3.5 months. The objective response rate of combination therapy was 2%, and 6-month progression-free survival was 48%. The most frequently reported grade 3–4 adverse events included fatigue (13%), hypertension (13%), and bleeding (13%). Close to 54% of the patients discontinued treatment due to adverse events, refusal of further treatment, or treatment delays. Three deaths occurred in the study, of which two were due to treatment-related bowel perforations. Given the minimal efficacy and increased toxicity seen with the combination of bevacizumab and temsirolimus, we do not recommend the use of this regimen in patients with advanced extra-pancreatic neuroendocrine tumors.
Role of the tumour microenvironment in bladder cancer pathogenesis and value of the reverse translational approach: a tale of two species
Ahmed, Basant H. , Cheville, John C. , Rancilio, Nicholas J. , Abel, Alex , Wierson, Wesley A. , McGill, Jodi L. , Mochel, Jonathan P. , Mochel, Jonathan P , Zdyrski, Christopher , Allenspach, Karin

Mayo Clinic

Clinical and Translational Discovery | September 13, 2023 | Volume: 3 | Issue: 5 | Pages: No page available

10.1002/ctd2.235 Get It

AbstractBackgroundBladder cancer is a significant malignancy in humans and canines, with high death rates and devastating clinical symptoms. Despite significant advances in therapeutic management over the years, only a small fraction of bladder cancer patients respond to immunotherapies as a second line of treatment. Since immunotherapies act on various cellular and molecular targets in the bladder cancer tumour microenvironment (TME), a greater understanding of the various types of immune cells, immune checkpoint molecules and cytokines involved in antitumour immunity will help to improve the success rate of current and novel immunotherapies, therefore enhancing the patients quality of life. Accumulating evidence shows fundamental similarities between human and canine muscle‐invasive bladder cancer (MIBC) in their clinical, histological and molecular features.AimThis review focuses on comparative aspects of MIBC in both species, highlighting the role that canines can play as a model for studying MIBC. Additionally, we discuss the various types of immune cells within bladder cancer TME that can influence the prognosis and response to immunotherapy and chemotherapy in both species.ConclusionIt remains challenging to recapitulate the heterogeneity and complexity of the bladder cancer tumour microenvironment using in vivo and in vitro models, such as zebrafish and 3D organoids models. Optimization of these techniques to create a more representative translational model has been facilitated through in vitro immune‐oncology cocultures, which are considered promising tools to help select the ideal individualized treatment options and predict disease prognosis.
Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: results from the MYONET registry
Hum, Ryan Malcolm , Lamb, Janine A. , Oldroyd, Alexander , Wang, Guochun , Wedderburn, Lucy R, Diederichsen, Louise Pyndt , Schmidt, Jens , Danieli, Maria Giovanna , Oakley, Paula, Griger, Zoltán , Phuong, Thuy Nguyen Thi , Kodishala, Chanakya , Mercado, Mónica Vázquez-Del , Andersson, Helena , Paepe, Boél De , Maurer, Britta , McCann, Liza , Pipitone, Nicolò , McHugh, Neil , New, Robert P, Ollier, William , Krogh, Niels Steen , Lundberg, Ingrid E. , Chinoy, Hector , Registry, MYONET, D’hose, Sophie, Lu, Xin , Tian, Xiaolan , Pleštilová, Lenka, Barochová, Tereza, Kubínová, Kateřina , Gelardi, Chiara, Paladini, Alberto , Piga, Mario Andrea , Jara, Luis J. , Cruz‐Reyes, Claudia , Andrade-Ortega, Lilia, Medrano-Ramírez, Gabriel , Salazar-Páramo, Mario , Chavarría-Ávila, Efrain , Aguilar-Vázquez, Andrea, Anda, Jesús-Aureliano Robles-De , Molberg, Øyvind , Dastmalchi, Maryam, Notarnicola, Antonella , Gheorghe, Karina, Liden, Maria, Hanna, Balsam , Jalal, Awat, Hellström, Helena, Martineus, Jehns Christian, New, Paul, Platt, Hazel, Ahmed, Yasmeen , Armstrong, Raymond, Bernstein, Robert, Black, Carol M., Butler, Robin, Carty, John , Chattopadhyay, Chandra, Chelliah, E G, Clarke, Fiona, Dawes, P. T., Devlin, Joseph, Edwards, Christopher, Emery, Paul , Fordham, J. L. A., Fraser, Alexander, Gaston, Hill, Gordon, Patrick , Griffiths, Bridget , Gunawardena, Harsha , Hall, Frances, Hanna, Michael G. , Harrison, Beverley, Hay, Elaine M. , Hilton‐Jones, David, Horden, Lesley, Jones, Adrian, Kamath, Sanjeet, Kennedy, Thomas J. , Klimiuk, P S, Knights, Sally, Lambert, John, Laxminarayan, Ramasharan, Lecky, Bryan, Marks, Jeffrey M., Martin, Michael F., McGonagle, Dennis , McHugh, Neil, McKenna, Francis, McLaren, John, McMahon, Michael , McRorie, Euan , Merry, P, Miller, James , Nicholls, Anne, Ong, Voon , Over, K. E., Packham, John, Pipitone, Nicolo, Plant, Michael, Pountain, G., Pullar, T, Roberts, Mark, Scott, David A. , Shadforth, M F, Sheeran, Thomas, Srinivasan, Arul, Swinson, David, Teh, Lee‐Suan , Webley, M, Winer, Jonathan M., Wedderburn, Lucy R. , Lilleker, James B , Lamb, Janine A , Oldroyd, Alexander G S , Wedderburn, Lucy R , Griger, Zoltan , Nguyen Thi Phuong, Thuy , Kodishala, Chanakya , Vazquez-Del Mercado, Monica , De Paepe, Boel , McHugh, Neil , Vencovsky, Jiri , Lundberg, Ingrid E , Chinoy, Hector , McCann, Liza J , Bleecker, Jan De , Vencovský, Jiří , Registry, MYONET, Mann, H. , Kryštůfková, Olga , Klein, Martin , Saavedra, Miguel A , Lastra, Olga Lidia Vera , Satoh, Minoru , Petri, Marcelo H. , Rönnelid, Johan , Lan, Nguyễn Thị Ngọc , Padyukov, Leonid , Rothwell, Simon W. , Bernstein, Robert, Bowman, Simon , Bruce, Ian N , Carty, John, Denton, Christopher P. , Edwards, Christopher, Fordham, John, Isaacs, John Dudley , Isenberg, David , Kitas, George D. , Lanyon, Peter , Luqmani, Raashid Ahmed , Machado, Pedro , Marks, Jeffrey, Martin, Michael, McHugh, Neil, Miles, Sarah, Nixon, Jennifer, Ong, Voon, Packham, John, Pipitone, Nicolo, Sanders, Paul W. , Williams, Brian, Winer, Jonathan

Mayo Clinic

Rheumatology | September 11, 2023 | Volume: 63 | Issue: 8 | Pages: 2093-2100

10.1093/rheumatology/kead481 | PMID 37698987 Get It

Abstract Objectives To compare clinical characteristics, including the frequency of cutaneous, extramuscular manifestations and malignancy, between adults with anti-synthetase syndrome (ASyS) and DM. Methods Using data regarding adults from the MYONET registry, a cohort of DM patients with anti-Mi2/-TIF1γ/-NXP2/-SAE/-MDA5 autoantibodies, and a cohort of ASyS patients with anti-tRNA synthetase autoantibodies (anti-Jo1/-PL7/-PL12/-OJ/-EJ/-Zo/-KS) were identified. Patients with DM sine dermatitis or with discordant dual autoantibody specificities were excluded. Sub-cohorts of patients with ASyS with or without skin involvement were defined based on presence of DM-type rashes (heliotrope rash, Gottron’s papules/sign, violaceous rash, shawl sign, V-sign, erythroderma, and/or periorbital rash). Results In total 1054 patients were included (DM, n = 405; ASyS, n = 649). In the ASyS cohort, 31% (n = 203) had DM-type skin involvement (ASyS-DMskin). A higher frequency of extramuscular manifestations, including Mechanic’s hands, Raynaud’s phenomenon, arthritis, interstitial lung disease and cardiac involvement differentiated ASyS-DMskin from DM (all P < 0.001), whereas higher frequency of any of four DM-type rashes—heliotrope rash (n = 248, 61% vs n = 90, 44%), violaceous rash (n = 166, 41% vs n = 57, 9%), V-sign (n = 124, 31% vs n = 28, 4%), and shawl sign (n = 133, 33% vs n = 18, 3%)—differentiated DM from ASyS-DMskin (all P < 0.005). Cancer-associated myositis (CAM) was more frequent in DM (n = 67, 17%) compared with ASyS (n = 21, 3%) and ASyS-DMskin (n = 7, 3%) cohorts (both P < 0.001). Conclusion DM-type rashes are frequent in patients with ASyS; however, distinct clinical manifestations differentiate these patients from classical DM. Skin involvement in ASyS does not necessitate increased malignancy surveillance. These findings will inform future ASyS classification criteria and patient management.
Spino-plastic surgery: A literature review of vascularized bone grafts and their uses in spine reconstruction
Jeger, Jonathan L. , Simoni, Alec , Rebecca, Alanna M. , Winocour, Sebastian, Kalani, Maziyar A. , Bohl, Michael A. , Ropper, Alexander E., Reece, Edward M., Jeger, Jonathan L , Shvedova, Maria

Mayo Clinic

Orthoplastic Surgery | September 9, 2023 | Volume: 14 | Issue: C | Pages: 15-22

10.1016/j.orthop.2023.09.003 Get It

ABSTRACT The role of plastic surgeons in the world of spine surgery is quickly evolving. The plastic surgeon now serves both a therapeutic and prophylactic role in addressing complications of complex and revision spine surgery. The field of Spino-plastic Surgery is characterized by the use of vascularized bone grafts (VBGs). VBGs are bone segments transferred on their corresponding muscular attachments without the inclusion of a named vessel. The bone graft is adequately vascularized through the connection of the tendon by Sharpey's fibers and their associated microvasculature. VBGs provide an autologous, pedicled tissue rearrangement option with osteoinductive properties and adequate structural support for complex spine reconstruction. VBGs are associated with a lower risk of adverse events and shorter times to fusion than allografts, and bypass the need for lengthy microsurgical anastomosis. Five types of VBGs for spine reconstruction are described in this article, including iliac crest, rib, occiput, scapula, and spinous process VBG. Virtually any vertebral level can be reached for arthrodesis using one or more of these VBGs. Highlights Vascularized bone grafts are bone segments transferred on muscular attachments without the inclusion of a named vessel.Vascularized bone grafts provide an autologous, pedicled tissue rearrangement option for complex spine reconstruction with a lower risk of adverse events and shorter times to fusion than allografts.Five types of vascularized bone grafts for spine reconstruction have been described: iliac crest, rib, occiput, scapula, and spinous process.Virtually any vertebral level can be reached for arthrodesis using one or more vascularized bone grafts.
The Global, Regional, and National Burden of Adult Lip, Oral, and Pharyngeal Cancer in 204 Countries and Territories
Collaborators, GBD 2019 Lip, Oral, and Pharyngeal Cancer, Compton, Kelly, Xu, Rixing, Mishra, Rashmi , Drangsholt, Mark, Antunes, José Leopoldo Ferreira , Acheson, Alistair, Lu, Dan , Wallace, Lindsey E., Kocarnik, Jonathan , Fu, Weijia , Dean, Frances , Pennini, Alyssa, Henrikson, Hannah , Alam, Shazia , Ababneh, Emad , Abdoun, Meriem , Abidi, Hassan , Ali, Hiwa Abubaker, Adane, Tigist Demssew , Ahmad, Aqeel , Rashid, Tarik A. , Hamad, Hanadi Al , Alahdab, Fares , Alimohamadi, Yousef, Alipour, Vahid, Anwar, Sumadi Lukman, Anyasodor, Anayochukwu Edward , Aravkin, Aleksandr Y. , Aruleba, Raphael Taiwo , Azadnajafabad, Sina , Azangou‐Khyavy, Mohammadreza , Badar, Muhammad , Barqawi, Hiba Jawdat , Bashir, Nasir Zeeshan , Bashiri, Azadeh, Benzian, Habib , Bhagat, Devidas S. , Bhojaraja, Vijayalakshmi S, Bouaoud, Souad, Braithwaite, Dejana , Брико, Н. И. , Chakraborty, Promit Ananyo , Chattu, Vijay Kumar , Chaurasia, Akhilanand , Chen, Mengxuan , Cho, William C. , Chu, Dinh‐Toi , Chukwu, Isaac Sunday , Chung, Eunice, Martins, Natália , Dadras, Omid , Dandona, Lalit , Dandona, Rakhi , Daneshpajouhnejad, Parnaz , Molla, Meseret Derbew , Dessalegn, Fikadu Nugusu, Digesa, Lankamo Ena , Dixit, Shilpi Gupta , Dixit, Abhinav , Djalalinia, Shirin , Tantawi, Maha El , Enyew, Daniel Berhanie, Erku, Daniel , Ezzeddini, Rana, Fagbamigbe, Adeniyi Francis , Falzone, Luca , Fetensa, Getahun, Fukumoto, Takeshi , Gebrehiwot, Mesfin , Ghashghaee, Ahmad , Golechha, Mahaveer , Goleij, Pouya , Gorini, Giuseppe , Guimarães, André Luiz Sena , Gupta, Sapna , Halboub, Esam , Hanif, Asif , Harorani, Mehdi , Hasani, Hamidreza, Hassan, Abbas M. , Hassen, Mohammed Bheser, Hay, Simon I , Herrera-Serna, Brenda Yuliana , Hosseinzadeh, Mehdi , Ilić, Irena , Isola, Gaetano , Jaiswal, Abhishek , Jani, Chinmay , Javaheri, Tahereh , Jayaram, Shubha, Joseph, Nitin , Kadashetti, Vidya, Karanth, Shama D. , Kaur, Harkiran , Keykhaei, Mohammad , Khader, Yousef , Khajuria, Himanshu , Khanali, Javad , Khatib, Mahalaqua Nazli , Kashani, Hamid Reza Khayat , Kim, Min Seo , Kompani, Farzad , Kurmi, Om , Lal, Dharmesh Kumar, Lee, Yo Han , Lim, Stephen S , Listl, Stefan , Lopukhov, Platon D , Mafi, Ahmad R , Malik, Ahmad Azam , Maulud, Sazan Qadir , Nasab, Entezar Mehrabi, Mirfakhraie, Reza , Misganaw, Awoke, Misra, Sanjeev , Mithra, Prasanna , Mohammad, Yousef , Moni, Mohammad Ali , Moraga, Paula , Mubarik, Sumaira , Murray, Christopher J L , Swamy, Sreenivas Narasimha, Narayana, Aparna Ichalangod, Nassereldine, Hasan , Natto, Zuhair S. , Nayak, Biswa Prakash , Negru, Șerban , Nggada, Haruna Asura , Núñez-Samudio, Virginia , Oancea, Bogdan , Padrón‐Monedero, Alicia , Pandey, Anamika , Patel, Jay , Pezzani, Raffaele , Piracha, Zahra Zahid , Rabiee, Navid , Radhakrishnan, Venkatraman , Rahmani, Amir M. , Rao, Sowmya J, Rath, Goura Kishor, Rawaf, David Laith , Rawassizadeh, Reza , Rezaei, Nazila, Rezapour, Aziz , Riad, Abanoub , Romero‐Rodríguez, Esperanza , Manjula, S, Chandan, S N , Saddik, Basema , Saeed, Umar , Safaei, Mohsen , Sahebazzamani, Maryam , Samy, Abdallah M , Santric-Milicevic, Milena M , Sathian, Brijesh , Satpathy, Maheswar , Šekerija, Mario , Senthilkumaran, Subramanian , Seylani, Allen, Shafaat, Omid , Sharew, Mequannent Melaku Sharew, Sharifi‐Rad, Javad , Shorofi, Seyed Afshin, Shrestha, Sunil , Malleshappa, Sudeep K Siddappa , Singh, Paramdeep , Sinha, Dhirendra Narain , Solomon, Yonatan , Suleman, Muhammad , Abdulkader, Rizwan Suliankatchi , Abkenar, Yasaman Taheri, Tan, Ker‐Kan , Tbakhi, Abdelghani, Thiyagarajan, Arulmani , Tovani‐Palone, Marcos Roberto , Volovăț, Simona Ruxandra , Westerman, Ronny, Wickramasinghe, Nuwan Darshana , Xiao, Hong , Zadnik, Vesna, Zare, Iman, Zhang, Zhi-Jiang , Force, Lisa M , Hugo, Fernando Neves , Hoogar, Praveen , Rezaei, Nazila , Rezaei, Nazila , Shivakumar, KM , Collaborators, GBD 2019 Lip, Oral, and Pharyngeal Cancer, Cunha, Amanda Ramos da , Kerr, Alexander Ross , Wallace, Lindsey E., Abd‐Elsalam, Sherief , Abu‐Gharbieh, Eman , Addo, Isaac Yeboah , Ahmad, Sajjad , Akonde, Maxwell , Al‐Maweri, Sadeq Ali , Alsharif, Ubai , Ansari‐Moghaddam, Alireza , Anwar, Sumadi Lukman, Arabloo, Jalal , Asaad, Malke, Ashraf, Tahira , Athari, Seyyed Shamsadin , Attia, Sameh , Baghcheghi, Nayereh , Banach, Maciej , Bardhan, Mainak , Bernabé, Eduardo , Bjørge, Tone , Călina, Daniela Cornelia , Carreras, Giulia , Dai, Xiaochen , Soltani, Reza Darvishi Cheshmeh , Darwesh, Aso Mohammad , Debela, Sisay Abebe , Dianatinasab, Mostafa , Sayed, Iman El , Gaewkhiew, Piyada , Gallus, Silvano , Gill, Paramjit Singh , Gomez, Ricardo Santiago , Gupta, Bhawna , Gupta, Veer Bala , Gupta, Vivek , Haj‐Mirzaian, Arvin , Halwani, Rabih , Hariyani, Ninuk , Hassanipour, Soheil , Hayat, Khezar , Holla, Ramesh , Horita, Nobuyuki , Hussain, Salman , Ilesanmi, Olayinka Stephen , Ilić, Milena , Jayarajah, Umesh , Kandaswamy, Eswar , Karaye, Ibraheem M. , Kauppila, Joonas H. , Tabari, Mohammad Amin Khazeei , Koohestani, Hamid Reza , Kumar, G Anil , Vecchia, Carlo La , Lal, Dharmesh Kumar, Landires, Iván , Lasrado, Savita , Ledda, Caterina , Libra, Massimo , Mahumud, Rashidul Alam , Mathur, Manu Raj , Meena, Jitendra Kumar , Meštrović, Tomislav , Mohammadi, Mokhtar, Mohammadi, Esmaeil , Mokdad, Ali H. , Morrison, Shane D. , Mozaffari, Hamid Reza , Nair, Tapas Sadasivan , Nouraei, Hasti , Olagunju, Andrew T , Bali, Ahmed Omar , Padubidri, Jagadish Rao , Pardhan, Shahina , Radhakrishnan, Raghu , Rahmani, Amir Masoud, Rahmanian, Vahid , Rao, Chythra R , Rawaf, Salman , Razeghinia, Mohammad Sadegh , Rezaei, Negar , Rezaei, Nima , Rezapour, Aziz , Roberts, Thomas J. , Roshandel, Gholamreza , Saeb, Mohammad Reza , Sahebkar, Amirhossein , Farrokhi, Amir Salek , Shahsavari, Hamid R. , Shamsoddin, Erfan , Shetty, Jeevan K. , Shivakumar, K. M. , Shobeiri, Parnian , Singh, Jasvinder A. , Singh, Garima Prateek , Talaat, Iman Mamdouh , Tiyuri, Amir , Unnikrishnan, Bhaskaran , Vo, Bay, Wang, Cong , Yu, Chuanhua , Yüce, Deniz , Yunusa, Ismaeel , Zoladl, Mohammad , Alahdab, Fares

Mayo Clinic

JAMA Oncology | September 7, 2023 | Volume: 9 | Issue: 10 | Pages: 1401

10.1001/jamaoncol.2023.2960 | PMID 37676656 Get It

ImportanceLip, oral, and pharyngeal cancers are important contributors to cancer burden worldwide, and a comprehensive evaluation of their burden globally, regionally, and nationally is crucial for effective policy planning.ObjectiveTo analyze the total and risk-attributable burden of lip and oral cavity cancer (LOC) and other pharyngeal cancer (OPC) for 204 countries and territories and by Socio-demographic Index (SDI) using 2019 Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study estimates.Evidence ReviewThe incidence, mortality, and disability-adjusted life years (DALYs) due to LOC and OPC from 1990 to 2019 were estimated using GBD 2019 methods. The GBD 2019 comparative risk assessment framework was used to estimate the proportion of deaths and DALYs for LOC and OPC attributable to smoking, tobacco, and alcohol consumption in 2019.FindingsIn 2019, 370 000 (95% uncertainty interval [UI], 338 000-401 000) cases and 199 000 (95% UI, 181 000-217 000) deaths for LOC and 167 000 (95% UI, 153 000-180 000) cases and 114 000 (95% UI, 103 000-126 000) deaths for OPC were estimated to occur globally, contributing 5.5 million (95% UI, 5.0-6.0 million) and 3.2 million (95% UI, 2.9-3.6 million) DALYs, respectively. From 1990 to 2019, low-middle and low SDI regions consistently showed the highest age-standardized mortality rates due to LOC and OPC, while the high SDI strata exhibited age-standardized incidence rates decreasing for LOC and increasing for OPC. Globally in 2019, smoking had the greatest contribution to risk-attributable OPC deaths for both sexes (55.8% [95% UI, 49.2%-62.0%] of all OPC deaths in male individuals and 17.4% [95% UI, 13.8%-21.2%] of all OPC deaths in female individuals). Smoking and alcohol both contributed to substantial LOC deaths globally among male individuals (42.3% [95% UI, 35.2%-48.6%] and 40.2% [95% UI, 33.3%-46.8%] of all risk-attributable cancer deaths, respectively), while chewing tobacco contributed to the greatest attributable LOC deaths among female individuals (27.6% [95% UI, 21.5%-33.8%]), driven by high risk-attributable burden in South and Southeast Asia.Conclusions and RelevanceIn this systematic analysis, disparities in LOC and OPC burden existed across the SDI spectrum, and a considerable percentage of burden was attributable to tobacco and alcohol use. These estimates can contribute to an understanding of the distribution and disparities in LOC and OPC burden globally and support cancer control planning efforts.
Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Ettinger, David S. , Wood, Douglas E. , Stevenson, James, Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , DeCamp, Malcolm M., Dilling, Thomas J. , Dowell, Jonathan E. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hughes, Miranda, Bharat, Ankit , Chang, Joe Y. , Chirieac, Lucian R. , Grotz, Travis E. , Hegde, Aparna , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 6, 2023 | Volume: 21 | Issue: 9 | Pages: 961-979

10.6004/jnccn.2023.0045 | PMID 37673108 Get It

Mesothelioma is a rare cancer originating in mesothelial surfaces of the peritoneum, pleura, and other sites. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on peritoneal mesothelioma (PeM). The NCCN Guidelines for PeM provide recommendations for workup, diagnosis, and treatment of primary as well as previously treated PeM. The diagnosis of PeM may be delayed because PeM mimics other diseases and conditions and because the disease is so rare. The pathology section was recently updated to include new information about markers used to identify mesothelioma, which is difficult to diagnose. The term “malignant” is no longer used to classify mesotheliomas, because all mesotheliomas are now defined as malignant.
Combining Celiac and Hepatic Vagus Nerve Neuromodulation Reverses Glucose Intolerance and Improves Glycemic Control in Pre- and Overt-Type 2 Diabetes Mellitus
Waataja, Jonathan J. , Asp, Anders J., Asp, Anders J., Billington, Charles J.

Mayo Clinic

Biomedicines | September 4, 2023 | Volume: 11 | Issue: 9 | Pages: 2452

10.3390/biomedicines11092452 | PMID 37760895 Get It

Neurological disorders and type 2 diabetes mellitus (T2DM) are deeply intertwined. For example, autonomic neuropathy contributes to the development of T2DM and continued unmanaged T2DM causes further progression of nerve damage. Increasing glycemic control has been shown to prevent the onset and progression of diabetic autonomic neuropathies. Neuromodulation consisting of combined stimulation of celiac vagal fibers innervating the pancreas with concurrent electrical blockade of neuronal hepatic vagal fibers innervating the liver has been shown to increase glycemic control in animal models of T2DM. The present study demonstrated that the neuromodulation reversed glucose intolerance in alloxan-treated swine in both pre- and overt stages of T2DM. This was demonstrated by improved performance on oral glucose tolerance tests (OGTTs), as assessed by area under the curve (AUC). In prediabetic swine (fasting plasma glucose (FPG) range: 101–119 mg/dL) the median AUC decreased from 31.9 AUs (IQR = 28.6, 35.5) to 15.9 AUs (IQR = 15.1, 18.3) p = 0.004. In diabetic swine (FPG range: 133–207 mg/dL) the median AUC decreased from 54.2 AUs (IQR = 41.5, 56.6) to 16.0 AUs (IQR = 15.4, 21.5) p = 0.003. This neuromodulation technique may offer a new treatment for T2DM and reverse glycemic dysregulation at multiple states of T2DM involved in diabetic neuropathy including at its development and during progression.
Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus
Bhat, Shubha , Lyu, Ruishen, Agarwal, Mitali, Becker, Michelle , Bloomfeld, Richard S. , Bruining, David H. , Cohen, Benjamin L, Ivanov, Marina, Leighton, Jonathan A. , Stewart, Alyssa P, Trocke, Lindsay, Tse, Stacy , Vaughn, Byron P. , Regueiro, Miguel, Sokn, Erick, Rieder, Florian , Cohen, Benjamin L, Stewart, Alyssa P., Ungaro, Ryan C. , Regueiro, Miguel

Mayo Clinic

Inflammatory Bowel Diseases | August 31, 2023 | Volume: 30 | Issue: 6 | Pages: 950-959

10.1093/ibd/izad143 | PMID 37650888 Get It

Abstract Background Given the complexity of inflammatory bowel disease (IBD) care, utilization of multidisciplinary teams is recommended to optimize outcomes. There is a growing recognition that clinical pharmacists should be an integral part of this care model. We sought to define the roles of IBD clinical pharmacists in the United States. Methods A national multidisciplinary expert panel of 12 gastroenterologists and clinical pharmacists practicing in IBD clinics was assembled. We used the RAND/University of California, Los Angeles appropriateness method, with a total of 281 statements generated based on a systematic literature review and expert opinion. Each statement was anonymously rated as appropriate, uncertain, or inappropriate in 2 rounds of voting. Results The number of publications evaluating the clinical pharmacists’ roles in IBD is limited, primarily focusing on thiopurine initiation and monitoring, medication adherence, and switching to biosimilars. Medication education; medication initiation and monitoring; therapeutic drug monitoring; biosimilar management; health maintenance review; and transitions of care were deemed by the panel to be appropriate roles for IBD clinical pharmacists. In considering real-world settings, IBD clinical pharmacists should practice clinically under a predefined scope and primarily focus on complex treatments (eg, immunomodulators, biologics, and small molecules). Clinical pharmacists should also be included in practice settings with IBD specialized physicians. Additionally, clinical pharmacists caring for patients with IBD should be residency trained and board certified. Conclusions This consensus defines IBD clinical pharmacists’ roles and provides a framework for embedded clinical pharmacists in IBD care.